The global ultrasound market has reached saturation. However, innovations in organ-specific imaging and the introduction of elastography features for cancer detection are creating niche markets for ultrasound.

This report examines the increasing adoption of ultrasound in both primary and secondary diagnosis. Manufacturers of ultrasound are introducing advanced equipment and probes for organ-specific imaging. Developments in elastography ultrasound over the past three years have provided new methods of cancer detection. Therapeutic uses of ultrasound are also covered.

Scope of this research

• Identify the market potential of the ultrasound market and the various ultrasound segments.
• Gain a quick and comprehensive understanding of the new innovations in ultrasound.
• Develop a framework for decision making by identifying the new advances that will shape the future of the ultrasound market.
• Benchmark performance against the leading ultrasound companies in terms of revenue growth and product launch capabilities.
• Learn from the business strategies of prominent ultrasound companies to target future growth markets effectively.

Research and analysis highlights

Regulatory entities have been imposing stringent regulations on imaging equipment manufacturers to lower the patient’s exposure to unwanted radiation, and this is favouring the use of ultrasound. There has also been an increase in the use of ultrasound owing to demographic effects and enhanced healthcare initiatives.

Ultrasound is not limited only to basic screening, but rather it is increasingly also being used for cancer detection and therapeutic purposes. Furthermore, developments such as 3D/4D imaging, elastography, and innovations in probe design have stimulated ultrasound sales in the last five years.

The emerging economies of Brazil, Russia, India, and China are for the first time investing in high-end product purchases owing to restructured government healthcare initiatives and the construction of new hospital facilities.

Key reasons to purchase this research

• Which will be the largest growth opportunities in the ultrasound market?
• What are the key drivers and resistors that will effect the growth of the ultrasound market?
• What are the new advances in ultrasound and which of the advances offer significant potential in the future?
• How have the leading companies built strong positions in the various segments of the ultrasound market?
• What is the trend in terms of new product launches in the various ultrasound segments?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/16206/The-Ultrasound-Market-Outlook-to-2016.html

Medical equipment report offering, “Belgium Patient Monitoring Market Outlook to 2016” provides key market data on the Belgium patient monitoring market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Multiparameter Patient Monitoring, Remote Patient Monitoring, Patient Monitoring Leads and Electrodes, Non-invasive Blood Pressure Monitors, Neonatal Monitors, Fetal Monitors and Micro-electromechanical Systems. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for seven patient monitoring market categories – Multiparameter Patient Monitoring, Remote Patient Monitoring, Patient Monitoring Leads and Electrodes, Non-invasive Blood Pressure Monitors, Neonatal Monitors, Fetal Monitors and Micro-electromechanical Systems.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the seven market categories.
• Global corporate-level profiles of key companies operating within the Belgium patient monitoring market.
• Key players covered include Philips Healthcare, GE Healthcare, Draegerwerk AG & Co. KGaA, OMRON HEALTHCARE Co., Ltd., Nihon Kohden Corporation, Mindray Medical International Limited and Medtronic, Inc.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Belgium patient monitoring competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

Philips Healthcare
GE Healthcare
Draegerwerk AG & Co. KGaA
OMRON HEALTHCARE Co., Ltd.
HARTMANN GROUP
A&D Medical / LifeSource
3M Health Care
Welch Allyn Inc.
The Dixion Company
Terumo Corporation
St. Jude Medical, Inc.
Spacelabs Healthcare, Inc.
Siemens Healthcare
Schiller AG
Rossmax International Ltd.
OSI Systems, Inc.
Nihon Kohden Corporation
Mindray Medical International Limited
Microlife Corporation
Mennen Medical Ltd.
Medtronic, Inc.
Larsen & Toubro Medical Equipment & Systems
GE Sensing & Inspection Technologies
Fukuda Denshi Co., Ltd.
Edwards Lifesciences Corporation
Edan Instruments, Inc.
Criticare Systems, Inc.
Covidien plc
CONMED Corporation
LifeWatch AG
Boston Scientific Corporation
BIOTRONIK SE & Co. KG
Bionet Co.,Ltd.
AViTA Corporation
Ambu A/S
Patient Monitoring Market Pipeline Products

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3143/Belgium-Patient-Monitoring-Market-Outlook-to-2016.html
———————————————-

“Dysmenorrhea – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global dysmenorrhea market. The report identifies the key trends shaping and driving the global dysmenorrhea market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global dysmenorrhea sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts
The global dysmenorrhea therapeutics market was valued at $1.7 billion in 2009. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% by 2016. This slow growth is primarily attributed to due to the lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. The current competitive landscape consists of only generics and off-label therapies, none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure.

Scope

The scope of the report includes:
- Annualized global dysmenorrhea market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases by the mechanism of action being developed and emerging trends. Key classes of mechanism of action include prostaglandin synthetase inhibitors and COX-2 inhibitors.
- Analysis of the current and future market competition in the global dysmenorrhea market. Key market players covered are China Aoxing Pharmaceutical Company, Vantia Therapeutics, Columbia Laboratories, Merck and Bayer Schering Pharma AG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, the unmet needs and the implications for the future market associated with dysmenorrhea.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dysmenorrhea market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global dysmenorrhea market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global dysmenorrhea market landscape? – Identify, understand and capitalize.

Companies Mentioned

China Aoxing Pharmaceutical Co., Inc
Merck
Vantia Therapeutics
Bayer Schering Pharma
Columbia Laboratories

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3104/Dysmenorrhea-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Acne – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acne market. The report identifies the key trends shaping and driving the global acne market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global acne sector. GlobalData’s research suggests that the global acne market was worth $2.8 billion in 2009. The moderate increase in revenues in the future is attributed to the overcrowding of the market with generics and the increased acceptance of alternative therapies such as photodynamic therapy and UV/blue light therapy. The current market has several products which act on acne by targeting different etiologic factors involved in the development of acne. Solodyn currently rules the acne market, followed by Doryx. The acne therapeutics market is witnessing a shift towards products which are a combination of two or more effective acne treatments. The currently marketed combination products such as Duac and Ziana are forecast to steadily increase their revenues.

Scope

The scope of the report includes:
- Annualized global acne market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include antimicrobials, combination therapies, antibacterial and anti-inflammatory, enzyme inhibitors, androgen antagonists, oxidizing agents and comedolytic agents.
- Analysis of the current and future market competition in the global acne market. The key market players covered are Steifel laboratories, Allergan, Galderma, & and Cosmo Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future acne market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global acne market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global acne market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global acne market landscape? – Identify, understand and capitalize.

Companies Mentioned

Cosmo Pharmaceuticals
Stiefel, a GSK company
Galderma S.A
Allergan Inc (Allergan)

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3103/Acne-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Candidiasis – Drug Pipeline Analysis and Market Forecasts to 2016”, provides an essential source of information and analysis on the global candidiasis market. The report identifies the key trends shaping and driving the global candidiasis market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global candidiasis market to reach $2,386m by 2016. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

Scope

The scope of the report includes:
- Annualized global candidiasis market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the United States (the US), the United Kingdom (the UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include monoclonal antibodies, cytochrome inhibitors, combination therapies, aminio acid sequences and antimicrobial peptides, selective immune response amplifiers, vaccines and protein synthesis inhibitors.
- Analysis of the current and future market competition in the global candidiasis market. The key market players covered Neutec Pharma PLC (a wholly owned subsidiary of Novartis AG), Novartis AG, Demegen, Inc. and Basilea Pharmaceutica Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future candidiasis market.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global candidiasis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global candidiasis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global candidiasis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Neutec Pharma PLC
Novartis AG
Demegen, Inc
Basilea Pharmaceutica Ltd

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3102/Candidiasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Hepatitis B – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global hepatitis B market. The report identifies the key trends shaping and driving the global hepatitis B market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hepatitis B (Hep B)sector.

GlobalData’s analysis revealed that the market grew at a Compound Annual Growth Rate (CAGR) of 5.9% since 2001 to reach $879m in 2009. Growth in the Hep B market will be driven by the increasing number of patients over the next few years. The current Hep B market is dominated by anti-viral therapies and this trend likely to continue, with no innovative molecules in the developmental pipeline. GlobalData’s analysis showed that the Hep B pipeline is weak in terms of the number of molecules. The pipeline molecules in the Hep B market primarily comprise of me-too molecules (five), and combination therapies (five), with efficacy and safety profiles similar to the present therapeutic options. The most promising molecules among them are combinations of entecavir plus adefovir and tenofovir plus emtricitabine.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global Hep B market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action are nucleoside/nucleotide anti-virals, glucocorticoids and Natural Killer Ts (NKTs).
- Analysis of the current and future market competition in the global Hep B market. The key market players covered are Bristol-Myers Squibb and Gilead Science Inc.
- Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, unmet needs, and the implications for the future market associated with Hep B.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis B market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis B market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global hepatitis B market landscape? – Identify, understand and capitalize.

Companies Mentioned

Bristol-Myers Squibb
Gilead Sciences, Inc

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3101/Hepatitis-B-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Tuberculosis – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Tuberculosis (TB) drugs market. The report identifies the key trends shaping and driving the global TB market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global TB sector. The global TB drugs market was worth $99m in 2009. The market is expected to decline by 2.8% during the next seven years. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have improved with the conventional DOTs (Directly Observed Therapy). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. Companies seem to be actively developing products for the prophylaxis and cure of TB that have lesser treatment durations. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to address the burden of TB in developed and developing nations. With the success of the ongoing clinical studies, the market is expected to witness a breakthrough in TB control and treatment. The vaccines’ primary focus would be to inhibit the infection at the first place. The global TB drugs market is heading towards a phase of decline as no launches are expected till 2016.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global Tuberculosis drugs market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action of drugs include ATP synthase inhibitors, protein synthesis inhibitors, cell wall synthesis inhibitors, DNA gyrase inhibitors, FAS synthase inhibitors, translocase-1 inhibitors and others. The vaccine candidates have been segmented as recombinant live vaccines, recombinant protein vaccines and viral vectored vaccines.
- Analysis of the current and future market competition in the global Tuberculosis drugs market. The key market players covered are isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin, rifabutin and capreomycin.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, the unmet needs and the implications for the future market associated with TB.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global tuberculosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global tuberculosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global tuberculosis market landscape? – Identify, understand and capitalize.

Companies Mentioned

TB Alliance, the US
Aeras (Aeras Global TB Vaccine Foundation), the US
Crucell, the Netherlands
Tibotec BVBA, Belgium

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3100/Tuberculosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Erectile Dysfunction – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Erectile Dysfunction (ED) therapeutics market. The report identifies the key trends shaping and driving the ED market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ED therapeutics sector. GlobalData’s analysis revealed that the market grew at a CAGR of 9.8% from 2001 to 2009. The growth rate was moderate due lack of ED awareness and reluctance among male general population to discuss their sexual problem. With the patent expiry of a key product, Viagra, in 2012, the market is expected to decline after 2011, resulting in a CAGR of 4% from 2009 to 2016.

GlobalDatas analysis showed that the ED pipeline is weak. The products in the ED pipeline comprises of me-too class. Some of the promising me-too class drugs/molecules are likely to get approval in coming years which are in phase III trials. One of the promising molecule include Avanafil , which is unlikely to have much impact as market has high competition among similar products and generic erosion after 2012 due to patent expiry of Viagra (sildenafil citrate).

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global ED therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include FKBP12 binder, serotonin and dopamine enhancer, PDE-5 inhibitor, and Alpha1A-adrenoreceptors antagonist.
- Analysis of the current and future market competition in the global ED therapeutics market. Key market players covered are VIVUS, Inc., and Rexahn Pharmaceuticals, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with ED.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global erectile dysfunction market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global erectile dysfunction market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global erectile dysfunction market landscape? – Identify, understand and capitalize.

Companies Mentioned

VIVUS, Inc
Rexahn Pharmaceuticals, Inc

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3099/Erectile-Dysfunction-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical report offering, “Herpes Simplex – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global herpes simplex market. The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global herpes simplex therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData finds that the global herpes simplex market was worth approximately $2.9 billion in 2009. The global herpes simplex therapeutics market is expected to grow at a CAGR of 11.1% between 2009 and 2016. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently the therapeutic regimen for Herpes Simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC products such as Abreva and Aviralex. This market is a significantly genericized market with many brands across the major seven geographies.

Scope

- Annualized global herpes simplex market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Key geographies covered in this report include the US (United States), the UK (united Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include DNA polymerase inhibitors, Helicase-primase inhibitors, NFkB regulators, HSV-2 gene and nectin-1 receptor targetters, viral maturation inhibitors and PDI inhibitors.
- Analysis of the current and future market competition in the global herpes simplex market. Key market players covered are BioAlliance Pharma, Nutra Pharma Corporation and AiCuris GmbH & Co. KG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with herpes simplex therapeutics.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global herpes simplex market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global herpes simplex market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global herpes simplex market landscape? – Identify, understand and capitalize.

Companies Mentioned

Bioalliance Pharma
Nutra Pharma Corporation
AiCuris GmbH and Co. KG

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3141/Herpes-Simplex-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical report offering, “Anemia – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global anemia market. GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a Compound Annula Growth Rate (CAGR) of 8.5% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. GlobalData evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. However, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global anemia market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, transforming growth factor (TGF)-beta inhibitors and transferrin receptor (TfR) targetters.
- Analysis of the current and future market competition in the global anemia market. Key future market players covered are Affymax, Pharmacosmos, Amgen Inc., Hoffmann-La Roche, Chugai – Pharmaceutical Celgene Corporation, Hoffmann-La Roche, and Johnson and Johnson.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the anemia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global anemia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anemia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global anemia market landscape? – Identify, understand and capitalize.

Companies Mentioned

Affymax
Pharmacosmos
Amgen Inc
Celgene Corporation
Chugai Pharmaceutical
Hoffmann-La Roche
Johnson & Johnson

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3140/Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-